Arpida Ltd. remains on track to file a new drug application in 2007 for its lead compound, iclaprim, which attained the primary endpoint in the first of two Phase III clinical trials by demonstrating statistical non-inferiority to linezolid (Zyvox) in the treatment of complicated skin and skin-structure infection (CSSSi). (BioWorld International) Read More
